Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behavioral Treatment With Agonist Maintenance
NCT00000311Phase 3Completed
- Sponsor
- Yale University
- Start
- Feb 1995
- Primary completion
- Feb 1999
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) and cocaine-related disorders (4 arms), sponsored by Yale University. Primary endpoints: Depression at 24 weeks, Withdrawal symptoms and 3 more. Started Feb 1995; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)cocaine-related disorders
Beyond the preview
Go deeper on NCT00000311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000311.